SEC Form 4 · accession 0001209191-19-008746
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James A Schoeneck
Director
Period of report
Feb 7, 2019
Accepted (ET)
Feb 8, 2019 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 7, 2019 | M | 2,000 | $2.90 | A | 29,700 | D | |
| Common StockF1 | Feb 7, 2019 | S | 2,000 | $57.17 | D | 27,700 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.90 | Feb 7, 2019 | M | 2,000 | D | — | Apr 27, 2020 | Common Stock | 2,000 | 8,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2Fully vested.